This is a confirmatory clinical investigation. The objective is to collect new additional clinical data demonstrating the safety and performance of the device in the contact-lens wearing population with dry eyes. The hypotheses are that T2769 improves dry eye symptomatology (e.g. decrease in CLDEQ-8 score, in OSDI score, ocular discomfort assessed by VAS) and signs (e.g. increase in Schirmer and TBUT, decrease in Oxford score) at D36, in comparison to baseline. The primary objective of this investigation is to assess the performance of T2769 in contact lens wearers with dry eye symptoms in terms of change from baseline (Day 1) to Day 36 (Final visit) in Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) total score.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
34
T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
Medical Center "Oxycom"
Burgas, Bulgaria
"Asmp Ob - Ip Glm" Eood
Smolyan, Bulgaria
Medical Center For Eye Health "Focus"
Sofia, Bulgaria
Specialized Ophthalmological Hospital For Active Treatment "Pentagram"
Sofia, Bulgaria
Medical Center "Vereya"
Stara Zagora, Bulgaria
Ambulatory For Group Practice For Specialized Medical Care For Eye Diseases - Dr. Grupchevi
Varna, Bulgaria
Change From Baseline in Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Total Score.
The primary endpoint is the change from baseline (Day 1) to Day 36 in the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) total score. CLDEQ-8 consists of 8 questions designed to measure dry eye symptoms specifically related to the use of contact lenses. The total score is obtained by adding the scores obtained for each answer. The final score is ranging from 1 to 37. 37 is the worst score.
Time frame: CLDEQ- score is assessed at Day 1 and Day 36
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.